来自MSN1 年
NRx Pharmaceuticals Nears Completion of Pivotal Trial for Bipolar Depression Treatment
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced that the last patient in its Phase 2b/3 study of NRX-101 recently completed their day 42 visit. The company is now preparing ...
Nasdaq14 天
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...